ALPMY vs. EXEL
ALPMY (Astellas Pharma Inc) and EXEL (Exelixis, Inc.) are both stocks. Both are in the Healthcare sector — ALPMY in Drug Manufacturers - General, EXEL in Biotechnology. Over the past 10 years, ALPMY returned -0.31%/yr vs 20.91%/yr for EXEL. At a 0.14 correlation, their price movements are largely independent.
Performance
ALPMY vs. EXEL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALPMY achieves a 1.35% return, which is significantly lower than EXEL's 17.16% return. Over the past 10 years, ALPMY has underperformed EXEL with an annualized return of -0.31%, while EXEL has yielded a comparatively higher 20.91% annualized return.
ALPMY
- 1D
- 0.15%
- 1M
- -5.21%
- YTD
- 1.35%
- 6M
- 1.89%
- 1Y
- 45.94%
- 3Y*
- -2.47%
- 5Y*
- -4.56%
- 10Y*
- -0.31%
EXEL
- 1D
- -1.08%
- 1M
- 2.39%
- YTD
- 17.16%
- 6M
- 11.17%
- 1Y
- 27.20%
- 3Y*
- 37.25%
- 5Y*
- 18.24%
- 10Y*
- 20.91%
ALPMY vs. EXEL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ALPMY Astellas Pharma Inc | 1.35% | 41.23% | -17.10% | -21.50% | -6.82% | 5.38% | -9.34% | 35.81% | -1.10% | -7.48% |
EXEL Exelixis, Inc. | 17.16% | 31.62% | 38.81% | 49.56% | -12.25% | -8.92% | 13.90% | -10.42% | -35.30% | 103.89% |
Correlation
The correlation between ALPMY and EXEL is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Dec 18, 2008 | 0.14 |
Fundamentals
ALPMY:
$24.21B
EXEL:
$13.73B
ALPMY:
¥172.03
EXEL:
$3.00
ALPMY:
12.65
EXEL:
17.13
ALPMY:
0.08
EXEL:
0.30
ALPMY:
1.72
EXEL:
6.01
ALPMY:
2.13
EXEL:
7.09
ALPMY:
¥2.27T
EXEL:
$2.38B
ALPMY:
¥1.69T
EXEL:
$1.70B
ALPMY:
¥445.01B
EXEL:
$991.79M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALPMY vs. EXEL — Risk / Return Rank
ALPMY
EXEL
ALPMY vs. EXEL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Astellas Pharma Inc (ALPMY) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALPMY | EXEL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.93 | ||
| Sortino ratioReturn per unit of downside risk | +1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.16 | +0.12 |
| Calmar ratioReturn relative to maximum drawdown | 2.17 | 1.09 | +1.08 |
| Martin ratioReturn relative to average drawdown | 5.85 | 2.62 | +3.23 |
Loading charts...
Drawdowns
ALPMY vs. EXEL - Drawdown Comparison
The maximum ALPMY drawdown since its inception was -83.67%, smaller than the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for ALPMY and EXEL.
Loading charts...
Drawdown Indicators
| ALPMY | EXEL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.67% | -97.38% | +13.71% |
Max Drawdown (1Y)Largest decline over 1 year | -21.28% | -25.16% | +3.88% |
Max Drawdown (3Y)Largest decline over 3 years | -40.38% | -25.34% | -15.04% |
Max Drawdown (5Y)Largest decline over 5 years | -49.11% | -36.12% | -12.99% |
Max Drawdown (10Y)Largest decline over 10 years | -49.67% | -57.20% | +7.53% |
Current DrawdownCurrent decline from peak | -75.12% | -4.02% | -71.10% |
Average DrawdownAverage peak-to-trough decline | -58.44% | -70.97% | +12.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.88% | 10.42% | -2.54% |
Volatility
ALPMY vs. EXEL - Volatility Comparison
Astellas Pharma Inc (ALPMY) and Exelixis, Inc. (EXEL) have volatilities of 9.83% and 9.41%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALPMY | EXEL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.83% | 9.41% | +0.42% |
Volatility (6M)Calculated over the trailing 6-month period | 22.43% | 25.55% | -3.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 28.73% | 40.36% | -11.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.42% | 37.19% | -11.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.59% | 44.49% | -18.90% |
Dividends
ALPMY vs. EXEL - Dividend Comparison
Neither ALPMY nor EXEL has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
ALPMY Astellas Pharma Inc | 0.00% | 1.93% | 2.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.20% | 2.18% |
EXEL Exelixis, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
ALPMY vs. EXEL - Financials Comparison
This section allows you to compare key financial metrics between Astellas Pharma Inc and Exelixis, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ALPMY vs. EXEL - Profitability Comparison
ALPMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Astellas Pharma Inc reported a gross profit of 457.56B and revenue of 647.49B. Therefore, the gross margin over that period was 70.7%.
EXEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exelixis, Inc. reported a gross profit of 0.00 and revenue of 610.81M. Therefore, the gross margin over that period was 0.0%.
ALPMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Astellas Pharma Inc reported an operating income of 113.89B and revenue of 647.49B, resulting in an operating margin of 17.6%.
EXEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exelixis, Inc. reported an operating income of 251.34M and revenue of 610.81M, resulting in an operating margin of 41.2%.
ALPMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Astellas Pharma Inc reported a net income of 57.97B and revenue of 647.49B, resulting in a net margin of 9.0%.
EXEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exelixis, Inc. reported a net income of 210.47M and revenue of 610.81M, resulting in a net margin of 34.5%.
Frequently Asked Questions
ALPMY and EXEL have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALPMY has higher volatility (9.83%) compared to EXEL (9.41%). In terms of maximum drawdown, ALPMY dropped -83.67% vs EXEL's -97.38%.
ALPMY currently has the higher Sharpe Ratio (1.61 vs 0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALPMY and EXEL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer